In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Nov 24, 2025 5:00 PM Eastern Standard Time Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma Share Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still in response at 24 months based on TRANSCEND MCL trial results PRINCETON, N.J.--(BUSINESS WIRE)--Bristol ...

for more on Novo and Pharmaceutical spring and Guggenheim's biotech analyst Sheamus Fernandez. Sheamus, your take on the Novo results. Uh yeah, so I guess it's not too surprising to the overall market uh what happened here.This was a high-risisk reward clinical study for Nova Nordisk. Um it was well communicated by the company that way. But that being said, uh the company has had a lot of challenges this year, largely from competition from Eli Liy, but it also faces pretty challenging year in 2026 and poten ...

Nov 24, 2025 8:05 AM Eastern Standard Time Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation Share New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044 PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant g ...

Core Viewpoint - Poxel SA is implementing a recovery plan to stabilize its financial situation and avoid liquidation, with new management focused on cost control and business development [3][5][6]. Recovery Plan Update - The recovery plan has been finalized, emphasizing commercial development for Imeglimine, PXL 770, and PXL 065, alongside significant cost reductions and clearing of liabilities [4][5]. - New financing commitments of up to €11.25 million from financial partners IPF and IRIS are aimed at supporting the recovery efforts [5][7]. - The plan requires approval from the Commercial Court of Lyon and will be presented to shareholders at the annual general meeting on December 11, 2025 [5][11]. Financial Structure and Capital Transactions - The recovery plan includes a capital increase with preferential subscription rights for existing shareholders, expected to be at a discount of 30% to 50% of the current share price [12][26]. - A capital increase reserved for IPF will be at a premium of 5% to 10% compared to the preferential subscription rights price [12][26]. - The restructuring aims to ensure that IPF retains approximately 29.9% of the company's share capital post-transaction [17][24]. Management and Strategic Focus - The new management team has been actively working since August to streamline operations and focus on core business areas, including potential partnerships for Imeglimine in Asia [6][9]. - The company plans to reduce administrative costs by transferring its listing to Euronext Growth, which will lower regulatory expenses [10][12]. Shareholder Engagement - A webinar is scheduled for November 26, 2025, to discuss the recovery plan and future prospects with shareholders [5][32]. - Shareholders will have the opportunity to vote on the proposed financial delegations and capital transactions during the upcoming general meeting [11][12].

The Tel Aviv Stock Exchange fell today. The Tel Aviv 35 Index fell 1.15% to 3,320.72 points, the Tel Aviv 125 Index fell 1.20% to 3,359.47 points; and the BlueTech Global Index fell 1.36% to 574.59 points. The All Bond corporate bond index rose 0.09% to 419.78 points. Turnover totalled NIS 1.54 billion in equities and NIS 1.97 billion in bonds. On the foreign exchange market, the representative shekel-dollar rate was set 0.644% higher on Friday, at NIS 3.28/$, and the representative shekel-euro rate was s ...

PresentationWelcome to day 3 of Stephens 2025 Investment Conference here at Nashville. I'm Mac Etoch, the Life Science Tools and Pharma Services Analyst. And I'm pleased to be joined by the team over at West Pharmaceuticals. John Sweeney, Head of IR; John McMahon, newly anointed Chief Financial Officer; As well as Shane Campbell, the Chief Proprietary Segment Officer.Robert McMahonSenior VP & CFO Yes. Thanks, Mac. It's great to be here. Really excited. This is my first time -- our first -- my first time att ...

Pharmaceutical chain Big Caring is considering an initial public offering in Kuala Lumpur next year, according to people familiar with the matter https://t.co/Pa6h8eTd3H ...

Company Performance - Home Depot's stock fell 6%, marking the worst performance in the S&P 500, after the company missed third-quarter earnings forecasts and lowered its full-year profit outlook due to a lack of storms and economic uncertainty affecting homeowner remodeling projects [4][9]. - Medtronic's stock rose approximately 5% after exceeding analysts' estimates for fiscal second-quarter sales and adjusted profit, driven by strong demand in its end markets [8][10]. Market Overview - Major U.S. equity indexes declined for the second consecutive day, with the S&P 500 dropping 0.8%, the Dow sliding 1.1%, and the Nasdaq losing 1.2%, ahead of several high-profile earnings reports and delayed jobs data [3]. - Concerns regarding high valuations in the artificial intelligence sector negatively impacted tech stocks, with Western Digital and Micron Technology shares falling 5.9% and 5.6%, respectively [5]. Regulatory Developments - Amazon and Microsoft shares decreased by 4.4% and 2.7%, respectively, following the announcement of investigations by European Union regulators into their cloud computing services [6].

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers Share PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) ("Bristol Myers Squibb†), today announced the accepted amounts and pricing terms of the previously announced tender offers to purchase for cash its outstanding notes listed in the tables below. The outstanding debt securities listed in (i) the first table below labeled "Pool 1†are referred to collectively as the "Pool 1 Notes†and (ii) the s ...

Core Points - Bristol Myers Squibb announced early participation results for its tender offers to purchase outstanding notes, with changes to the maximum aggregate purchase prices for both Pool 1 and Pool 2 Notes [1][9] - The company has decreased the maximum purchase price for Pool 1 Notes from $4 billion to an amount sufficient to accept all validly tendered notes, while increasing the maximum for Pool 2 Notes from $3 billion to accommodate all validly tendered notes with priority levels 1 through 4, plus up to $250 million of 5.900% Notes due 2033 [1][8] - The early settlement date for the offers is set for November 20, 2025, with the offers expiring on December 3, 2025, unless extended [9][10] Pool 1 Notes Summary - The total principal amount of Pool 1 Notes validly tendered by the early tender deadline includes $360 million of 4.950% Notes due 2026, $529.9 million of 3.200% Notes due 2026, $519.5 million of 4.900% Notes due 2027, and $560.1 million of 4.900% Notes due 2028 [5][8] - Bristol Myers Squibb does not anticipate accepting any additional tenders of Pool 1 Notes after the early tender deadline due to the maximum purchase price being met [8] Pool 2 Notes Summary - The total principal amount of Pool 2 Notes validly tendered includes $6.2 million of 6.875% Debenture due 2097, $879.2 million of 6.400% Notes due 2063, $811.5 million of 6.250% Notes due 2053, and $1.3 billion of 5.650% Notes due 2064 [7][8] - No Pool 2 Notes with acceptance priority levels 6 through 9 will be accepted for purchase [8] Additional Information - All accepted notes will be cancelled and retired, ceasing to be outstanding obligations of Bristol Myers Squibb [11] - Holders of accepted notes will receive cash payments for accrued and unpaid interest in addition to their total consideration [10]